Contraceptive Technology Update
RSSArticles
-
Offer Reproductive Life Planning for Adolescents
The CDC recommends all persons capable of having a child create a reproductive life plan.
-
Research Looks at Antibiotic Option for Gonorrhea
A drug under investigation could be used as an alternative to ceftriaxone injection as a component of recommended therapy for gonorrhea, replacing the need for intramuscular injection.
-
College Health Services Are Making the Grade
College health centers are playing a pivotal role in the introduction and performance of timely sexually transmitted infection screenings.
-
Does Weight Gain Play a Role in Women’s Contraceptive Choices?
Concerns about weight gain may be driving contraception choices, new data released by Penn State College of Medicine indicate.
-
LARC for the Medically Complicated Patient
Few medical conditions are absolute contraindications to long-acting reversible contraceptive methods.
-
Just Two HPV Shots Recommended for Younger Teens
The CDC now recommends that 11- to 12-year-olds receive two doses of HPV vaccine at least six months apart, rather than the previously recommended three doses.
-
Link Between Early Menopause, Higher Risk of Fracture Confirmed
A new analysis of data from the Women’s Health Initiative trial indicates an increased risk of fracture among women who reported early menopause (age 40 or younger), regardless of whether they were treated with hormone therapy and/or calcium and vitamin D supplementation.
-
Data Indicate Male Birth Control Shot May Be Effective
Men may be able to use birth control shots to prevent pregnancy in their female partners, data suggest in a just-published Phase II study.
-
Check Reproductive Health Considerations for Women Presenting with Rheumatoid Arthritis
Women diagnosed with rheumatoid arthritis must consider their drug treatment when choosing a contraceptive. Current treatment practice is to prescribe non-biologic disease-modifying antirheumatic drugs, which reduce disease activity and prevent joint deformity, within three months of diagnosis.
-
Data Support Five-year Use of Liletta
Data from a recent analysis of the 52 mg levonorgestrel Liletta intrauterine device indicate its calculated levonorgestrel content and release rate curves support the continued evaluation of its contraceptive use for five or more years.